107 related articles for article (PubMed ID: 22035418)
21. Association of ABCB1 polymorphisms with the efficacy of ondansetron in chemotherapy-induced nausea and vomiting.
He H; Yin JY; Xu YJ; Li X; Zhang Y; Liu ZG; Zhou F; Zhai M; Li Y; Li XP; Wang Y; Zhou HH; Liu ZQ
Clin Ther; 2014 Aug; 36(8):1242-1252.e2. PubMed ID: 25012726
[TBL] [Abstract][Full Text] [Related]
22. Influence of UGT1A1 polymorphisms on the outcome of acute myeloid leukemia patients treated with cytarabine-base regimens.
Chen P; Zhu KW; Zhang DY; Yan H; Liu H; Liu YL; Cao S; Zhou G; Zeng H; Chen SP; Zhao XL; Yang J; Chen XP
J Transl Med; 2018 Jul; 16(1):197. PubMed ID: 30016963
[TBL] [Abstract][Full Text] [Related]
23. Influence of BCL2-938C>A and BAX-248G>A promoter polymorphisms in the development of AML: case-control study from South India.
Cingeetham A; Vuree S; Dunna NR; Gorre M; Nanchari SR; Edathara PM; Meka P; Annamaneni S; Digumarthi R; Sinha S; Satti V
Tumour Biol; 2015 Sep; 36(10):7967-76. PubMed ID: 25957891
[TBL] [Abstract][Full Text] [Related]
24. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.
Schneider C; Oellerich T; Baldauf HM; Schwarz SM; Thomas D; Flick R; Bohnenberger H; Kaderali L; Stegmann L; Cremer A; Martin M; Lohmeyer J; Michaelis M; Hornung V; Schliemann C; Berdel WE; Hartmann W; Wardelmann E; Comoglio F; Hansmann ML; Yakunin AF; Geisslinger G; Ströbel P; Ferreirós N; Serve H; Keppler OT; Cinatl J
Nat Med; 2017 Feb; 23(2):250-255. PubMed ID: 27991919
[TBL] [Abstract][Full Text] [Related]
25. Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment.
Megías-Vericat JE; Montesinos P; Herrero MJ; Moscardó F; Bosó V; Martínez-Cuadrón D; Rojas L; Rodríguez-Veiga R; Boluda B; Sendra L; Cervera J; Poveda JL; Sanz MÁ; Aliño SF
Leuk Lymphoma; 2017 Dec; 58(12):2880-2894. PubMed ID: 28573946
[TBL] [Abstract][Full Text] [Related]
26. Impact of single nucleotide polymorphisms of cytarabine metabolic genes on drug toxicity in childhood acute lymphoblastic leukemia.
Gabor KM; Schermann G; Lautner-Csorba O; Rarosi F; Erdelyi DJ; Endreffy E; Berek K; Bartyik K; Bereczki C; Szalai C; Semsei AF
Pediatr Blood Cancer; 2015 Apr; 62(4):622-8. PubMed ID: 25557962
[TBL] [Abstract][Full Text] [Related]
27. Association between NME1 polymorphisms and cancer susceptibility: A meta-analysis based on 1644 cases and 2038 controls.
Shi X; Jin H; Peng M; Li B; She M; Zhu T; Wen S; Qin D
Pathol Res Pract; 2018 Apr; 214(4):467-474. PubMed ID: 29525404
[TBL] [Abstract][Full Text] [Related]
28. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E
J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565
[TBL] [Abstract][Full Text] [Related]
29. STAT5 gene polymorphisms are associated with the response of acute myeloid leukemia patients to Ara-C-based chemotherapy.
Xu P; Zhou D; Ouyang J; Chen B
Leuk Lymphoma; 2016; 57(4):921-6. PubMed ID: 26384082
[TBL] [Abstract][Full Text] [Related]
30. Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase.
Falk IJ; Fyrberg A; Paul E; Nahi H; Hermanson M; Rosenquist R; Höglund M; Palmqvist L; Stockelberg D; Wei Y; Gréen H; Lotfi K
Am J Hematol; 2013 Dec; 88(12):1001-6. PubMed ID: 23873772
[TBL] [Abstract][Full Text] [Related]
31. Variability in transport and biotransformation of cytarabine is associated with its toxicity in peripheral blood mononuclear cells.
Parmar S; Seeringer A; Denich D; Gärtner F; Pitterle K; Syrovets T; Ohmle B; Stingl JC
Pharmacogenomics; 2011 Apr; 12(4):503-14. PubMed ID: 21521023
[TBL] [Abstract][Full Text] [Related]
32. SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival.
Mahlknecht U; Dransfeld CL; Bulut N; Kramer M; Thiede C; Ehninger G; Schaich M
Leukemia; 2009 Oct; 23(10):1929-32. PubMed ID: 19458626
[No Abstract] [Full Text] [Related]
33. Genome-wide genotype-based risk model for survival in core binding factor acute myeloid leukemia patients.
Park S; Choi H; Kim HJ; Ahn JS; Kim HJ; Kim SH; Mun YC; Jung CW; Kim DDH
Ann Hematol; 2018 Jun; 97(6):955-965. PubMed ID: 29500710
[TBL] [Abstract][Full Text] [Related]
34. Genome-wide genotype-based risk model for survival in acute myeloid leukaemia patients with normal karyotype.
Choi H; Jung C; Sohn SK; Kim S; Kim HJ; Kim YK; Kim T; Zhang Z; Shin ES; Lee JE; Moon JH; Kim SH; Kim KH; Mun YC; Kim H; Park J; Kim J; Kim D
Br J Haematol; 2013 Oct; 163(1):62-71. PubMed ID: 24159609
[TBL] [Abstract][Full Text] [Related]
35. E2F1 rs3213150 polymorphism influences cytarabine sensitivity and prognosis in patients with acute myeloid leukemia.
Liu Y; Chen P; Chen G; Chen X
Ann Hematol; 2023 Dec; 102(12):3345-3355. PubMed ID: 37665348
[TBL] [Abstract][Full Text] [Related]
36. Role of Genetic Polymorphisms of Deoxycytidine Kinase and Cytidine Deaminase to Predict Risk of Death in Children with Acute Myeloid Leukemia.
Medina-Sanson A; Ramírez-Pacheco A; Moreno-Guerrero SS; Dorantes-Acosta EM; Sánchez-Preza M; Reyes-López A
Biomed Res Int; 2015; 2015():309491. PubMed ID: 26090398
[TBL] [Abstract][Full Text] [Related]
37. Genomic Variants of Cytarabine Sensitivity Associated with Treatment-Related Mortality in Pediatric AML: A Report from the Children's Oncology Group.
Phillips CL; Lane A; Gerbing RB; Alonzo TA; Wilkey A; Radloff G; Lange B; Gamazon ER; Dolan ME; Davies SM
Clin Cancer Res; 2020 Jun; 26(12):2891-2897. PubMed ID: 32122921
[TBL] [Abstract][Full Text] [Related]
38. SLC29A1 (ENT1) polymorphisms and outcome of complete remission in acute myeloid leukemia.
Kim JH; Lee C; Cheong HS; Koh Y; Ahn KS; Kim HL; Shin HD; Yoon SS
Cancer Chemother Pharmacol; 2016 Sep; 78(3):533-40. PubMed ID: 27422302
[TBL] [Abstract][Full Text] [Related]
39. [Relationship between the expression of the genes encoding the key enzymes for cytarabine metabolism and the pharmacokinetics of cytarabine in the treatment of childhood acute leukemia with high-dose cytarabine].
Xie XT; Jiang SY; Li BS; Yang LL
Zhonghua Er Ke Za Zhi; 2008 Apr; 46(4):276-80. PubMed ID: 19099730
[TBL] [Abstract][Full Text] [Related]
40. Significant association of genetic polymorphism of human nonmetastatic clone 23 type 1 gene with an increased risk of endometrial cancer.
Wang PH; Yi YC; Tsai HT; Tee YT; Ko JL; Han CP; Liu YF; Lin LY; Yang SF
Gynecol Oncol; 2010 Oct; 119(1):70-5. PubMed ID: 20599259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
